Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 16737874.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To test the hypothesis that metformin during lactation versus formula feeding would have no adverse effects on infants' growth, motor-social development, or intercurrent illness. Growth, motor-social development, and illness requiring a pediatrician visit were assessed in 61 nursing infants (21 male, 40 female) and 50 formula-fed infants (19 male, 31 female) born to 92 mothers with polycystic ovary syndrome (PCOS) taking a median of 2.55 g metformin per day throughout pregnancy and lactation. Within sex, at 3 and 6 months of age, weight, height, and motor-social development did not differ (p > or = .06) between breast- and formula-fed infants. No infants had retardation of growth, motor, or social development. Intercurrent illnesses did not differ. Metformin during lactation appears to be safe and effective in the first 6 months of infancy.
Medical subject headings
- Breast Feeding
- Hypoglycemic Agents
- Infant, Newborn
- Metformin
- Polycystic Ovary Syndrome
- Pregnancy Complications